Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.

Life (Basel) · 2021 · PMC8399988 · PMID 34440488

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Tezepelumab Nominally significant improvements in prebronchodilator FEV1 versus placebo were observed in all tezepelumab groups from Week 4 through to the end of the study (120–150 mL at Week 52) [ 12 ].

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.